Tracy Saxton

Managing Director at Dolby Family Ventures

Tracy Saxton

Tracy Saxton

Managing Director at Dolby Family Ventures

Overview
Career Highlights

Pivotal Bioventure Partners Investment Advisor LLC
Aucupo Biosciences

RelSci Relationships

3250

Number of Boards

8

Contact Data
Trying to get in touch with Tracy Saxton? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Tracy Saxton likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Roche Ventures

Relationship likelihood: Strong

Co-Founder at Millendo Therapeutics US, Inc.

Relationship likelihood: Strong

Venture Partner at SV Health Investors LLP

Relationship likelihood: Strong

Investment Director at Roche Venture Fund

Relationship likelihood: Strong

Managing Partner at Pivotal Bioventure Partners Investment Advisor LLC

Relationship likelihood: Strong

Founder at Levensohn Venture Partners LLC

Relationship likelihood: Strong

Managing Director at Dolby Family Ventures

Relationship likelihood: Strong

Venture Partner at Pivotal Bioventure Partners Investment Advisor LLC

Relationship likelihood: Strong

Professor, Chair of Thermosciences at Stanford University

Relationship likelihood: Strong

Co-Founder at Purigen Biosystems, Inc.

Relationship likelihood: Strong

Paths to Tracy Saxton
Potential Connections via
Relationship Science
You
Tracy Saxton
Managing Director at Dolby Family Ventures
Education
MBA
Class of 2011

Columbia Business School (CBS) is the business school of Columbia University in Manhattan, New York City. It was established in 1916 to provide business training and professional preparation for undergraduate and graduate Columbia University students. It is one of six Ivy League business schools and its admission process is among the most selective of top business schools.

PhD in Molecular Genetics
Class of 1999

Established in 1827, the University of Toronto has one of the strongest research and teaching faculties in North America, presenting top students at all levels with an intellectual environment unmatched in depth and breadth on any other Canadian campus. With more than 82,000* students across three campuses (St. George, Mississauga and Scarborough) and over 500,000 alumni active in every region of the world, U of T's influence is felt in every area of human endeavour.

BSc in Biology

Born in 1965, SFU has become Canada's leading comprehensive university with vibrant campuses in British Columbia's largest municipalities — Vancouver, Burnaby and Surrey — and deep roots in partner communities throughout the province and around the world.

Memberships
Fellow
Current

The Society of Kauffman Fellows is a network of venture capitalists operating at 160 venture firms and corporate venture groups in 26 countries on 6 continents, collectively deploying $50B in venture capital.

Career History
Professional
Prior

Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA.

Professional
Prior

Cyterix Pharmaceuticals, Inc. develops cancer therapeutics. It develops cancer therapeutics based on a proprietary OncoCY prodrug discovery approach. The company was founded by Paul R. Ortiz De Montellano, Luis Bayol and Steven A. Everett on April 10, 2010 and is headquartered in San Francisco, CA.

Project Team Leader
2004 - 2007

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Boards & Committees
Director
Prior - 2018

Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in Foster City, CA.

Director
Prior - 2017

PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ.

Director
2017 - 2017

Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Tracy Saxton. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Tracy Saxton's profile does not indicate a business or promotional relationship of any kind between RelSci and Tracy Saxton.